Ipragliflozin, a sodium–glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial
2019 ◽
Vol 10
(4)
◽
pp. 1012-1021
◽
Keyword(s):
Fat Mass
◽
2018 ◽
Vol 12
(5)
◽
pp. 617-624
◽
Keyword(s):
2013 ◽
Vol 27
(5)
◽
pp. 501-507
◽
2011 ◽
Vol 109
(6)
◽
pp. 481-485
◽
Keyword(s):
2012 ◽
Vol 45
(04)
◽
pp. 319-325
◽
Keyword(s):